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EDITORIAL REVIEW
Sickle cell nephropathy: New insights into its pathophysiology
In recent years new information clarified our ideas on the
pathophysiology of the nephropathy in sickle cell anemia
(SCA). Whereas the medullary vascular pathology with its
subsequent disturbances in renal concentrating and acidifying
capacity are well documented [1—4], in recent years more
attention has been given to the changes in cortical functions.
Not only did renal blood flow and glomerular filtration rate
(GFR) appear to be elevated, but proximal tubular activity,
both reabsorptive and secretory, also were found to be increased.
Arguments suggest that this hyperfiltration with increased prox-
imal tubular activity is secondary to the medullary changes and
mediated by abnormalities in renal vasoactive substances.
Sickle cell nephropathy thus is no longer confined to the
medullary changes per se; it extends to a more complex entity
with changes in cortical functions which compensate for a
defective water and sodium conservation in the medulla.
In this work we will first briefly review the well known
medullary abnormalities, both anatomical and functional, and
focus thereafter on the changes in renal hemodynamics and
proximal tubular functions, particularly with respect to their
pathophysiology. Finally, we will discuss the role of renal
vasoactive hormones in this entity.
Medullary anatomy
Interstitial edema with fibrosis is present in the medulla of
patients with sickle cell anemia [4]. More detailed information
on the medullary vascular pathology was obtained by
microradioangiographic studies (Fig. 1). With this technique it
was demonstrated that vasa recta are almost completely absent
in SCA patients (with SS hemoglobin). The few vessels that are
present are spiral, dilated, and blindly ending [51. The frequent
occurrence of hematuria, both microscopic and macroscopic,
seems a logical consequence of these vascular abnormalities
which ultimately can lead to papillary necrosis. Indeed,
hematuria can be one of the most dramatic manifestations of
SCA [31. Patients with the sickle cell trait (with AS hemoglobin)
have a reduced number of vasa recta with a loss of the normal
bundle architecture. With this severe pathology in the medul-
lary vascular system, the functions of water and electrolyte
transport in the medulla will be compromised too. The conse-
quences of this compromise for the handling of water, hydro-
gen, and potassium will be discussed next.
Medullary functions
Renal water excretion. In homozygote patients maximum
urine osmolality after 24-hr water deprivation is reduced to
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about 400 to 450 mOsm/kg of water [6—b]. Although in the
homozygote patients younger than 10 to 15 years, this concen-
trating defect is reversible after multiple transfusions with
normal blood; no improvement in maximum urine osmolality
was observed after red blood cell transfusion in patients above
this age [6, 9]. In heterozygote patients there is a gradual
decrease in concentrating capacity with age and only in subjects
over 50 to 60 years, maximum urine osmolality cannot rise
above the level of 450 mOsm/kg of water [10].
These findings of a defective concentrating mechanism have
been interpreted as the consequence of the above-mentioned
sickling and obstruction in the medullary vasculature. The
obliteration of vasa recta interferes with an adequate counter-
current multiplication and exchange system of Henle's long
loops. The microradioangiographic studies thus offer the visible
proof of the defect in renal concentrating capacity in SCA [11].
In contrast to this defect in renal water conservation, renal
diluting capacity is normal in SCA. After water loading the fall
in urine osmolality is similar in control subjects and SCA
patients [6, 81.
The capacity to generate negative free water (TCH2O) was
studied using different protocols. After saline infusion Hatch,
Culbertson, and Diggs [8] and Forrester and Alleyne [12] agreed
that TCH2O was impaired in SCA patients. From these studies it
was concluded that SCA patients exhibit a defect in the loop of
Henle that affects the transport of solute [12]. One could state
that the normal free water clearance argues against such an
impairment in sodium reabsorption from the ascending limb of
Henle's loop. However, a normal free water clearance only
indicates a normal transport mechanism in the thick part of the
ascending limb in the outer medulla, whereas a normal TCH2O
depends on adequate function of the part of Henle's loop
localized in the inner medulla. In agreement with this conclu-
sion is the fact that the concentrating defect is confined to the
level of 450 mOsm/kg of water. Thus, SCA patients are able to
increase osmolality to the level which can be built up in the
outer medulla. The pathology in the vasa recta, as shown in
Figure 1, is not contradictory to this conclusion of an adequate
outer medullary transport. The capillary plexus surrounding
short loops of Henle in the outer zone not necessarily pen-
etrates in the inner zone. In contrast, a separation between the
capillary plexus in these two zones is suggested [131. One could
thus assume that in SCA the outer medullary circulation is
adequate and the vascular pathology in particular is confined to
the inner zone.
In summary, sickling in vasa recta induces microtrombi,
infarction, and collateral formation of blood vessels. As a
consequence there is a defect in zonation and countercurrent
exchange. This results in an insufficient trapping of solute in the
inner medulla leading to abnormalities in renal water conserva-
tion (Fig. 2, left part).
Renal hydrogen and potassium excretion. SCA patients have
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Fig. 1. Microradioangiograph of a kidney from a control subject, showing normal vasa recta (left) and from a patient with sickle cell anemia, with
the absence of the vasa recta (right).
an incomplete form of distal tubular acidosis: After ammonium
chloride loading, urine pH does not fall below 5.3. Titratable
acid excretion is impaired [14—16], whereas ammonium excre-
tion is either normal [14, 151 or decreased [16]. Only after a
maximal acidifying stimulus, for instance, by sodium sulphate
infusion, SCA patients may lower urine pH and increase acid
excretion like control subjects [14, 15] Other evidence of a
defect in distal tubular hydrogen ion excretion was obtained by
studies on urine to blood Pco2 gradients after bicarbonate
loading. These were found depressed in SCA patients [17]. Acid
excretion in patients with the sickle cell trait is normal [15, 17].
Potassium excretion is also impaired in SCA patients [16, 18].
After potassium chloride administration or sodium sulphate
infusion as well as after furosemide, potassium excretion was
subnormal. Plasma renin activity and plasma aldosterone con-
centration in these patients were normal, both in standard
conditions and after volume contraction [161. The disturbance
in potassium excretion could be due to an abnormality in the
distal tubule secondary to the ischemic injury, which could also
apply to the defect in water excretion and hydrogen ion
excretion. The decreased potassium excretion, however, has
not been well explored and other pathogenetic mechanisms
could be involved. On the other hand, potassium excretion in
patients with the sickle cell trait is normal [19].
Renal hemodynamics
In infants and young adults with SCA, increased values for
both effective renal blood flow (ERBF) and GFR have been
established [20—221. Because there is a proportionally greater
rise in ERBF compared to GFR, filtration fraction is decreased,
suggesting a dilatation of the efferent arteriole. The increase in
renal blood flow cannot be explained by the anemia per se since
multiple transfusions with normal red blood cells do not reduce
the supernormal ERBF and GFR [9]. It is thus tempting to
regard this increase in renal hemodynamics as an intrinsic
characteristic of sickle cell nephropathy which is related to the
medullary abnormalities.
Histological investigations are consistent with the phenom-
enon of glomerular hyperfiltration. Microscopic studies have
shown glomerular enlargement, most marked in juxtamedullary
glomeruli, particularly in children [4, 23, 24]. Also in adult
patients glomerular size as well as total glomerular area per unit
area cortex have been found greater than in control subjects
[25].
Although in some adults supernormal values for GFR and
ERBF are exhibited [I], renal function generally decreases in
the older patients with SCA. Morgan and Sergeant [26] found a
creatinine clearance lower than 80 ml/min/l .73 m2 in six out of
25 patients over 40 years of age. Proteinuria of more than 100
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Fig. 2. Schematical representation of the consequences of sickling in the vasa recta for renal function in sickle cell anemia.
mg per day was common in this subgroup. The same investiga-
tors from Jamaica showed that renal failure is one of the most
common causes of death in older patients with SCA [271. They
did not find a cause for this renal failure. At necropsy shrunken
endstage kidneys were seen.
How can we explain this course in renal function with an
initial hyperfiltration, followed by chronic renal failure? In this
context a recent study of Tejani et al [281 is of particular
importance. In eight out of 13 children in whom a renal biopsy
was performed for persistent proteinuria or nephrotic syndrome
glomerulosclerosis was found, whereas in the other five patients
mesangial proliferation was found. Children with glomerulo-
sclerosis were older at the onset of nephropathy and presented
with the nephrotic syndrome more frequently than those with
mesangial proliferation. Also case reports mention nephrotic
syndrome due to focal glomerulosclerosis in SCA [4, 29, 30].
Minor proteinuria is a too-frequent finding (in some series
occurring in about one-third of the patients [31]) to conclude
that it is a fortuitous association. This sheds new light on
hyperfiltration and the increased glomerular surface area, pre-
sent in children and adolescents with this disease. As has been
shown in the remnant kidney model, hyperfiltration per se was
found to result in glomerulosclerosis [32]. The gradual decrease
in renal function in the older ages and the frequent proteinuria
in SCA thus can be explained by such a hyperfiltration-
mediated glomerulosclerosis.
Nephrotic syndrome due to membranous glomerulopathy
[25] or autologous immune complex nephritis has also been
described in SCA [33]. The latter is suggested to be secondary
to complexes of renal tubular epithelial antigen—released after
renal ischemia—with specific antibodies [33].
With increasing frequency SCA patients exhibit a need for
renal replacement therapy. Both hemodialysis [34] and trans-
plantation [35—37] can be performed successfully. Chatterjee
[36] showed that these patients do just as well as others after
transplantation with respect to patient and graft survival. Inter-
estingly, hematocrit values after transplantation are found to be
higher (± 30%) than in SCA patients with normal renal func-
tion. We observed a disturbance in the renal concentrating
capacity with a maximum urinary osmolality of 400 mOsm/kg of
water in one patient within 12 months after transplantation. No
information is yet available about the recurrence of glomerular
pathology after transplantation.
Proximal tubular function
Whereas in SCA severe disturbances in medullary transport
are documented, proximal tubular activity, both secretory and
reabsorptive, is supernormal.
Secretory capacity. The tubular transport maximum of para-
aminohippurate is elevated in SCA, particularly in children [20].
Other evidence of an increased proximal tubular secretory
capacity has been obtained from studies regarding uric acid
excretion. Notwithstanding the increased red cell turnover with
consequent uric acid overproduction, most patients with SCA
are normouricemic. Urate clearance was found greater in these
patients [38]. This increased urate clearance was accounted for
by increased pyrazinamide suppressible urate clearance indicat-
ing an increased secretion of urate [38, 39]. Hyperuricemia also
can occur with decreased urate clearance, but these patients
often have decreased para-aminohippurate clearance [39], pro-
teinuria [40], or decreased inulin clearance [411.
In addition, creatinine secretion is found elevated with a 20 to
25% rise in fractional creatinine excretion in SCA patients
compared to control subjects [42]. One should thus realize that
creatinine clearance in SCA overestimates GFR considerably.
Reabsorptive capacity. Tubular reabsorption, particularly of
phosphate, has been studied extensively. Maximum tubular
reabsorption of phosphate per liter of glomerular filtrate
(TmP/GFR) is increased in SCA. Consequent to this higher
phosphate reabsorption, serum phosphate is elevated in these
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Table 1. The effects of a 3-day indomethacin treatment (2 x 75 mg orally in the Retard formula) on salt and water balance;
the mean SEM is given
Indomethacin
Sickle cell anemia, N = 7 Control persons, N = 7
(—) (+) P value (—) (4-) P value
Body weight, kg 50.2 5.0 50.3 5.0 NS 62.5 3.9 63.6 4.1 P=0.05
Serum sodium,
mmoleslliter 135.3 0.5 136.4 0.4 NS 137.7 0.5 138,3 0.5 NS
Serum chloride,
mmoles/Iiter 103.1 1.0 105.3 0.7 NS 101.3 0.8 102.4 0.4 NS
Serum urea,
mmoleslliter 3.0 0.7 5.7 0.8 P = 0.02 4.5 0.2 4.8 0.2 NS
Serum osmolality,
mOsm/kg of wafer 279 2 287 2 P = 0.02 281 2 282 2 NS
Diuresis,ml/24hr 1560 160 1400 110 NS 1500 190 970 130 P0.05
Natriuresis,
mmolesf24 hr 79 15 39 9 P = 0.02 72 15 34 6 P = 0.05
subjects [17, 43, 441. It has been concluded that the high
phosphUe reabsorption reflects an increased reabsorptive ac-
tivity of the proximal tubule [431. Because sodium reabsorption
in the proximal tubule runs parallel to phosphate reabsorption,
this increased TmP/GFR suggests increased sodium reabsorp-
tion in the proximal tubule. This could be interpreted as an
independent and primary mechanism characteristic for sickle
cell nephropathy. Indeed, some studies mention an increased
plasma volume in non-crisis steady-state SCA patients [45, 461.
On the other hand, one could consider this increased proximal
tubular sodium reabsorption as a secondary mechanism to
correct for defects in medullary functions [431. One should
expect these patients to develop a volume-depleted state as a
consequence of the defects in medullary water and sodium
conservation. However, they adjust remarkably well to sodium
conservation. Thus, other factors known to influence renal
sodium excretion probably counter-regulate the tendency for
medullary sodium and volume loss. In this way the increased
proximal tubular reabsorption thus could be interpreted.
An increased tubular uptake of beta-2-microglobulin also has
been described in SCA [471. A positive correlation between the
reabsorption of phosphate and beta-2-microglobulin was de-
tected. Because the tubular maximum for beta-2-microglobulin
reabsorption was not exceeded, the positive correlation be-
tween phosphate and beta-2-microglobulin reabsorption is fur-
ther evidence of an increased activity of the proximal tubule in
SCA [47].
Therefore, we can summarize that SCA patients on the one
hand have a defect in renal medullary functions with a tendency
to lose water and sodium, whereas, on the other hand, RBF,
GFR, and proximal tubular activity are increased. In general,
the ultimate result is a normal sodium balance (Fig. 2).
Because renal blood flow, glomerular filtration, and solute
handling are regulated by the equilibrium between renal
vasoconstrictor (renin-angiotensin) and vasodilator (prostaglan-
dins) substances, we will now discuss the role of these hor-
mones in SCA.
Renal vasoactive hormones
Renin and aldosterone values in general are found normal in
SCA, both under standard and volume-depleted conditions [16,
421, although some studies reported increased plasma renin
activity [48, 491. Information on renal prostaglandins has been
obtained both indirectly by studying the effects of the
prostaglandin synthesis inhibitor, indomethacin, on renal hemo-
dynamics and sodium and water excretion and directly by
measuring prostaglandin excretion. Whereas indomethacin did
not change GFR and ERBF in control subjects, a significant fall
in these functions was found after indomethacin administration
to SCA patients [42]. This suggests that prostaglandins are of
importance in maintaining the supernormal or normal GFR and
ERBF in SCA. Prostaglandins may therefore be relevant with
respect to the hyperfiltration in young SCA patients. Because
prostaglandin production in the kidney is promoted by various,
often vasoconstrictor, stimuli, it is quite conceivable that isehe-
mic damage to the inner medulla in SCA induces synthesis of
vasodilator prostaglandins. Indeed, the interstitial cells of the
medulla contain aggregates of granular electron dense material
[23], which might be compatible with increased prostaglandin
synthesis in these cells (Fig. 2, right side). This will induce a rise
in RBF, particularly in the medullary nephrons, with a conse-
quent rise in GFR. This prostaglandin-mediated hyperfiltration
is thought to promote the occurrence of glomerulosclerosis with
an ultimate loss of renal function and chronic renal failure in
SCA. The rise in RBF and GFR also contribute to the increased
proximal tubular activity in these patients.
The effects of prostaglandin synthesis inhibition on sodium
and water metabolism are shown in Table 1. During a 3-day
course of indomethacin, sodium retention was observed in
control subjects and SCA patients. This was associated with a
decreased diuresis and a rise in body weight in the control
subjects, whereas in the SCA group no water retention oc-
curred and body weight did not change. In the latter group,
serum osmolality and serum urea increased significantly [50].
Because indomethacin in normal subjects is known to promote
sodium reabsorption in the medulla with a consequent rise in
papillary sodium and chloride concentration [511, the response
after indomethacin in SCA patients once more shows the
inability to maintain a concentration gradient in the medulla in
SCA. In these patients solute reabsorption was not followed by
water reabsorption and thus serum osmolality and urea rose
[42, 52]. This is also evident from the studies on the effects of
indomethacin on renal concentrating capacity (Fig. 3, left
panel). Whereas indomethacin induced a rise in urine osmolal-
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Fig. 3. Effect of indomethacin (75 mg as a suppository) in the water-depleted state (left part) and the effect of indomethacin (0.25 mg/kg body weigh
intravenously) in the water-loaded state (right part). The broken lines represent the means SEM in control subjects and the continuous line
represent the individual data in patients with sickle cell anemia. (Reproduced with permission from [521)
ity in control subjects, urine osmolality did not change at all in
the SCA patients [52], which favors a solute washout in the
inner medulla of these patients [1]. This is not mediated by renal
prostaglandins (Fig. 2, left part), but is the consequence of the
medullary abnormalities per se.
The effects of indomethacin on renal diluting capacity, how-
ever, are quite different. In control subjects, a slight water and
sodium retention occurred after indomethacin; urine osmolality
did not change. In contrast, a distinct fall in diuresis with a
significant rise in urine osmolality was seen when idomethacin
was given to the SCA group (Fig. 3, right panel). Thus, after
indomethacin the diluting capacity in SCA deteriorates, sug-
gesting that an apparently normal diluting capacity in these
patients depends on an adequate renal prostaglandin synthesis
[52]. Water reabsorption in the collecting duct is promoted by
vasopressin, whereas this effect of vasopressin is modulated by
prostaglandins. A normal osmolality-vasopressin interaction in
SCA has been demonstrated recently [531. This report excludes
that the rise in urine osmolality after indomethacin administra-
tion in these water-loaded patients is due to an insufficiently
suppressed vasopressin. Secondly, the rise in urine osmolality
after indomethacin could be explained by a decrease in GFR
with a consequent slowing of flow through the distal tubule
allowing some reabsorption of water in the absence of vasopres-
sin [54, 55]. Indeed, as shown before, GFR fell after indometh-
acm [421. Similarly, in this diluted state GFR decreased, al-
though not significantly, approximately 15%. Fractional sodium
excretion also fell. The percentage decrease in sodium excre-
tion was not different between the SCA patients and the control
subjects [52]. We argue then that it is not only the change in
filtration with a concomitant fall in sodium excretion which
accounts for the change in urine flow and in osmolality after
indomethacin in SCA patients. Since thirdly, prostaglandins are
known to promote blood flow, particularly to the inner cortical
nephrons [56], and indomethacin shifts blood flow to the
superficial regions [56, 571, the blood flow to the medulla might
be impaired in this way after indomethacin. In the SCA patients
with supposed stimulated prostaglandin synthesis, this decre-
ment in n'edullary blood flow will then favor the creation of an
osmotic gradient, at least in the outer medulla. This results in
water reabsorption and a rise in urine osmolality in this diluted
state. In fact, an adequate renal prostaglandin synthesis pro-
tects the SCA patient for a defect in renal diluting capacity.
Referring again to Figure 2, the effects of an increase in renal
blood flow with a rise in blood flow to the outer medulla are
shown on the right side of the figure. The consequence is a
solute washout in the outer medulla which thus is prostaglandin
mediated. This can explain the discrepancy of a normal diluting
capacity with a severe defect in renal concentrating capacity in
SCA. Only after prostaglandin synthesis inhibition can the
defect in renal diluting capacity be demonstrated.
Recently, more evidence was obtained for the theory of an
increase in renal vasodilating prostaglandins in SCA. Both in
the dehydrated and the diluted state, prostaglandin E2 excretion
was normal, whereas urine prostaglandin F20) was significantly
decreased. This resulted in a high E2IF2a ratio [58]. Since
prostaglandin E2 and F20) have different and sometimes opposite
effects on renal hemodynamics [591, renin release [601, and
sodium and water excretion [591, it seems plausible that an
abnormal balance between these prostaglandins is responsible
for some of the characteristics in sickle cell nephropathy.
Indeed it is suggested that the ratio between PGE2 and PGF20)
may be physiologically more important than the absolute levels
of the individual prostaglandins, at least with respect to renin
release [61]. In fact, the relative excess of the vasodilating
prostaglandin E2 can explain the rise in renal blood flow and
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Fig. 4. Mean SD of systolic and diastolic blood pressure in control
subjects (dotted lines) and patients with sickle ce/I anemia (closed
lines), age- and sex-matched. (Derived from [66]).
GFR, particularly in the juxtamedullary nephrons. Interest-
ingly, the studies in essential hypertension show the reverse.
Urinary PGE2 was found lower in essential hypertension than in
control subjects [62, 63] and, moreover, the PGE2/F2, ratio was
found decreased in hypertensive subjects [631. The latter au-
thors suggested that this impaired E2/F2a ratio in hypertension
could be due to the well-known tendency toward decreased
sodium reabsorption in the proximal nephron in essential hyper-
tension [63]. In view of these considerations, it is of importance
to note that blood pressure, diastolic as well as systolic, is lower
in SCA patients compared to age and sex-matched control
subjects (Fig. 4), or differently, the prevalence of hypertension
is significantly less in SCA patients [64—661. Further studies are
warranted to show whether or not these different blood pres-
sure readings in SCA are related to the described renal ab-
normalities.
We thus can conclude that the pathology in sickle cell
nephropathy is not only confined to the lesions in the renal
medulla. These medullary vascular lesions implicate changes in
water and sodium handling which, however, are compensated
for by changes in other segments of the nephron. Evidence
arises that the latter is mediated by an increase in renal
vasodilating prostaglandins. The characteristic lesion of the
kidney in SCA thereby offers an interesting model to study
renal function in general. The way in which abnormalities in
renal medullary functions are counterbalanced in this disease
can lead to insight in the water and salt handling in other kidney
diseases as well.
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